Clinical Trial

Can the Risk for AMD be Modulated?

Study acronym: AMD_LifeGene
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this Cross-sectional, interventional study is to learn about whether different risk factors, as Mediterranean diet, lifestyle and concomitant medication can modulate the risk imprinted by genetics in Age-related macular degeneration (AMD). The main question it aims to answer is: How the genetic risk interacts with environmental and lifestyle factors, especially Mediterranean diet and chronic medication, in order to assess how this interplay protects or presents higher risk for the establishment or the progression of AMD. Participants: Vital Signs will be measured; Medical History, Demographics, Nutritional/lifestyle habits and Family History of AMD will be recorded; Ophthalmological Examination will be performed Genetic analysis will be performed.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-02-09; most recent amendment 2025-09-22.
Status change: Recruiting → Active, Not Recruiting 2025-01-28
Status change: Active, Not Recruiting → Recruiting 2024-02-01
Status change: Not Yet Recruiting → Active, Not Recruiting 2023-06-20
Trial Details
NCT Number NCT05735730
Lead Sponsor Association for Innovation and Biomedical Research on Light and Image
Conditions Age-Related Macular Degeneration (ARMD)
Enrollment 1,800 participants
Start Date 2023-06-26
Primary Completion 2025-02-06 (estimated)
Study Completion 2028-01-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-23